Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases
The Academy, led by Professor Ravi P Mahajan CBE, is set to harmonize the efforts of various Apollo entities
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The grant is designated for the research and development of Pyronaridine
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
Subscribe To Our Newsletter & Stay Updated
